ERAS · Insider trading · 13F holders · Congress trades
Erasca, Inc. (ERAS)
Who is buying and selling ERAS: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 28
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $0
- Congress trades, 12 months
- 0
ERAS at a glance
- No open-market insider purchases or sales of ERAS were filed in the last 90 days.
- 28 13F filers hold ERAS among their 50 largest positions, worth $2.5B combined, including Robert Pohly and Oleg Nodelman. The biggest bets by portfolio weight are ARCH Venture Management, LLC (11.8%), Frazier Life Sciences Management, L.P. (10.0%) and Venrock Adviser, LLC (9.9%). In their latest 13Fs, 2 managers opened a new position and 10 added to one.
- No member of Congress has disclosed a trade in ERAS.
ERAS insider trading
No open-market insider purchases or sales of ERAS were filed in the last 90 days.
Who owns ERAS? Hedge funds and superinvestors
28 13F filers hold ERAS among their 50 largest positions, worth $2.5B combined, including Robert Pohly and Oleg Nodelman. The biggest bets by portfolio weight are ARCH Venture Management, LLC (11.8%), Frazier Life Sciences Management, L.P. (10.0%) and Venrock Adviser, LLC (9.9%). In their latest 13Fs, 2 managers opened a new position and 10 added to one.
Superinvestors holding ERAS: Robert Pohly 0.7% · Oleg Nodelman 0.3%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P.Hedge fund | 10.0% | $457.5M | 24,975,188 | +1.2% shares | Q2 2026 |
| Rtw Investments, LPHedge fund | 2.8% | $328.8M | 17,946,754 | +11.1% shares | Q2 2026 |
| Venrock Adviser, LLCHedge fund | 9.9% | $327.8M | 17,891,812 | +9.2% shares | Q2 2026 |
| Logos Global Management LPHedge fund | 9.6% | $222.6M | 12,150,000 | +9.0% shares | Q2 2026 |
| Siren, L.L.C.Investment manager | 4.2% | $208.8M | 11,397,781 | +1.4% shares | Q2 2026 |
| Paradigm Biocapital Advisors LPHedge fund | 3.3% | $175.0M | 9,550,000 | -8.1% shares | Q2 2026 |
| ARCH Venture Management, LLCVenture capital | 11.8% | $129.9M | 7,091,557 | +0.0% shares | Q2 2026 |
| Cormorant Asset Management, LPHedge fund | 5.6% | $109.9M | 6,000,000 | +3.4% shares | Q2 2026 |
| Affinity Asset Advisors, LLCHedge fund | 4.8% | $96.2M | 5,250,000 | -1.9% shares | Q2 2026 |
| Vivo Capital, LLCHedge fund | 6.9% | $75.6M | 4,127,412 | -66.0% shares | Q2 2026 |
| a16z Capital Management, L.L.C.Hedge fund | 0.4% | $52.4M | 2,862,500 | +0.0% shares | Q2 2026 |
| Soleus Capital Management, L.P.Hedge fund | 1.7% | $49.5M | 2,700,000 | — | Q2 2026 |
| Robert PohlyHedge fund | 0.7% | $41.3M | 2,256,986 | — | Q2 2026 |
| Stempoint Capital LPHedge fund | 5.0% | $28.7M | 1,565,913 | +552.8% shares | Q2 2026 |
| Rock Springs Capital Management LPHedge fund | 1.3% | $25.7M | 1,402,150 | +27.1% shares | Q2 2026 |
| Evergreen Quality Fund GP, Ltd.Asset manager | 0.4% | $25.2M | 1,375,300 | New | Q2 2026 |
| Silverarc Capital Management, LLCHedge fund | 2.6% | $23.1M | 1,263,026 | -31.8% shares | Q2 2026 |
| First Turn Management, LLCInstitutional asset manager | 2.4% | $22.4M | 1,221,721 | +40.8% shares | Q2 2026 |
| Caption Management, LLCHedge fund | 0.7% | $19.1M | 1,041,225 | — | Q2 2026 |
| Integral Health Asset Management, LLCHedge fund | 0.8% | $18.3M | 1,000,000 | +42.9% shares | Q2 2026 |
| Polymer Capital Management (HK) LTDHedge fund | 0.9% | $8.8M | 478,020 | +33.6% shares | Q2 2026 |
| KVP Capital Advisors, LPHedge fund | 6.1% | $8.3M | 455,000 | +33.8% shares | Q2 2026 |
| Spruce Street Capital LPHedge fund | 1.5% | $7.7M | 422,543 | +0.0% shares | Q2 2026 |
| Oleg NodelmanHedge fund | 0.3% | $6.0M | 330,000 | -63.3% shares | Q2 2026 |
| Seven Fleet Capital Management LPHedge fund | 0.9% | $5.6M | 308,007 | +38.5% shares | Q2 2026 |
| Acuta Capital Partners, LLCHedge fund | 3.4% | $4.9M | 265,199 | -25.2% shares | Q2 2026 |
| HighVista Strategies LLCHedge fund | 0.7% | $2.9M | 160,328 | -11.5% shares | Q2 2026 |
| Ishara Investments LPHedge fund | 0.6% | $751K | 41,000 | New | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 28). Screen ERAS in the grand portfolio →
ERAS stock trades by members of Congress
No member of Congress has disclosed a trade in ERAS.
ERAS questions and answers
Are insiders buying ERAS stock?
No open-market insider purchases or sales of ERAS were filed in the last 90 days.
Which hedge funds own ERAS?
28 13F filers hold ERAS among their 50 largest positions, worth $2.5B combined, including Robert Pohly and Oleg Nodelman. The biggest bets by portfolio weight are ARCH Venture Management, LLC (11.8%), Frazier Life Sciences Management, L.P. (10.0%) and Venrock Adviser, LLC (9.9%). In their latest 13Fs, 2 managers opened a new position and 10 added to one.
Has Congress traded ERAS?
No member of Congress has disclosed a trade in ERAS.
Who is the largest holder of ERAS?
Among 13F filers, Frazier Life Sciences Management, L.P. reports the largest ERAS position, $457.5M (24,975,188 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is ARCH Venture Management, LLC's: 11.8% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.